Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Outlicenses PARP Inhibitor To Clovis

This article was originally published in The Pink Sheet Daily

Executive Summary

Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.

You may also be interested in...



Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design

Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.

U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs

Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.

U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs

Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel